Equities researchers at Cowen began coverage on shares of Personalis (NASDAQ:PSNL) in a research note issued on Monday, Marketbeat reports. The firm set an “outperform” rating on the stock.
PSNL has been the topic of a number of other research reports. Morgan Stanley reissued an “equal weight” rating and set a GBX 230 ($3.01) price target on shares of BT Group in a research report on Monday. Oppenheimer initiated coverage on Personalis in a research report on Monday. They set an “outperform” rating and a $29.00 price target on the stock. Finally, Bank of America reissued a “buy” rating and set a $78.00 price target on shares of Citigroup in a research report on Monday. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Personalis currently has a consensus rating of “Buy” and an average target price of $28.25.
Shares of NASDAQ PSNL opened at $22.57 on Monday. Personalis has a twelve month low of $21.73 and a twelve month high of $31.88.
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.
Featured Article: Bull Market
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.